Raymond James Financial Inc. bought a new position in shares of ARK Genomic Revolution ETF (BATS:ARKG – Free Report) in the fourth quarter, HoldingsChannel reports. The fund bought 86,079 shares of the company’s stock, valued at approximately $2,027,000.
Several other large investors have also recently bought and sold shares of ARKG. Hemington Wealth Management lifted its holdings in ARK Genomic Revolution ETF by 44.6% during the 4th quarter. Hemington Wealth Management now owns 1,310 shares of the company’s stock worth $30,000 after buying an additional 404 shares during the last quarter. Union Bancaire Privee UBP SA acquired a new stake in shares of ARK Genomic Revolution ETF during the 4th quarter worth about $45,000. National Bank of Canada FI raised its position in shares of ARK Genomic Revolution ETF by 28.4% during the 3rd quarter. National Bank of Canada FI now owns 4,155 shares of the company’s stock worth $106,000 after acquiring an additional 920 shares in the last quarter. ARK Investment Management LLC lifted its stake in ARK Genomic Revolution ETF by 72.7% during the fourth quarter. ARK Investment Management LLC now owns 5,989 shares of the company’s stock worth $141,000 after purchasing an additional 2,521 shares during the last quarter. Finally, IHT Wealth Management LLC acquired a new position in ARK Genomic Revolution ETF in the third quarter valued at approximately $203,000.
ARK Genomic Revolution ETF Price Performance
ARKG stock opened at $21.52 on Monday. ARK Genomic Revolution ETF has a twelve month low of $21.37 and a twelve month high of $31.16. The company’s 50 day moving average is $25.34 and its two-hundred day moving average is $24.99.
ARK Genomic Revolution ETF Company Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Further Reading
- Five stocks we like better than ARK Genomic Revolution ETF
- How to trade using analyst ratings
- Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners
- What is a Bond Market Holiday? How to Invest and Trade
- MarketBeat Week in Review – 03/24 – 03/28
- Most active stocks: Dollar volume vs share volume
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
